Zentalis Advances Azenosertib Dose in DENALI Phase 2

Zentalis Pharmaceuticals ( (ZNTL) ) has issued an announcement.

On April 9, 2026, Zentalis Pharmaceuticals announced that a prespecified interim analysis from Part 2a of its DENALI Phase 2 trial in Cyclin E1-positive platinum-resistant ovarian cancer supported selecting a 400mg once-daily, 5-days-on/2-days-off regimen as the optimal monotherapy dose of azenosertib, showing a meaningfully higher response rate than 300mg on the same schedule with comparable safety and fewer treatment-related discontinuations. The company will carry this dose into the ongoing DENALI Part 2 trial and its ASPENOVA Phase 3 confirmatory study expected to start in the second quarter of 2026, has expanded DENALI with a new Part 2c cohort to reflect evolving treatment patterns, targets completion of DENALI Part 2 enrollment and topline data by year-end 2026, and reported $245.9 million in cash and securities at December 31, 2025, which it expects will fund operations into late 2027.

DENALI Part 2 is structured to support potential accelerated approval, with Part 2b expanding enrollment at the selected dose to about 100 patients and Part 2c adding roughly 40 patients previously treated with taxane-containing regimens, while all Part 2a patients contribute to the overall safety database. These trial refinements and the secured cash runway underscore Zentalis’s focus on advancing azenosertib through late-stage development in a clearly defined ovarian cancer subset and maintaining strategic flexibility as it progresses toward potential regulatory milestones.

The most recent analyst rating on (ZNTL) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Zentalis Pharmaceuticals stock, see the ZNTL Stock Forecast page.

Spark’s Take on ZNTL Stock

According to Spark, TipRanks’ AI Analyst, ZNTL is a Neutral.

The score is held down primarily by weak financial performance (ongoing losses, cash burn, and shrinking equity base). Offsetting this are constructive technical trends and a positive corporate update (clear 2026 milestones and stated cash runway), while valuation provides limited support due to a negative P/E and no dividend yield data.

To see Spark’s full report on ZNTL stock, click here.

More about Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing azenosertib, an orally available, non-chemotherapy treatment candidate targeting Cyclin E1-positive platinum-resistant ovarian cancer. The company is positioning azenosertib as a potential best-in-class therapy, with development centered on biomarker-selected ovarian cancer populations.

Average Trading Volume: 782,911

Technical Sentiment Signal: Buy

Current Market Cap: $195.8M

For detailed information about ZNTL stock, go to TipRanks’ Stock Analysis page.